The Japanese guideline for prostate cancer screening

Japanese Journal of Clinical Oncology

Volumn 39, Issue 6, 2009, Pages 339-351

  Hamashima, Chisato ^a   Nakayama, Tomio ^b   Sagawa, Motoyasu ^c   Saito, Hiroshi ^a   Sobue, Tomotaka ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer screening; Digital rectal examination; Guideline; Prostate cancer; Prostate specific antigen; Recommendation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HEMATURIA; HEMOSPERMIA; HUMAN; JAPANESE; MEDLINE; NEEDLE BIOPSY; POPULATION BASED CASE CONTROL STUDY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM HEMORRHAGE; REVIEW; SYSTEMATIC REVIEW; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HEALTH PLANNING GUIDELINES; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 66449099341     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp025     Document Type: Review

References (93)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan. Cancer mortality (1959-2005). http://ganjoho.ncc.go.jp/ professional/statistics/
2. Hisamichi S. Guidelines for cancer screening programs. Tokyo: Japan Public Health Association 2001 (in Japanese).
3. Hamashima C, Saito H, Nakayama T, Nakayama T, Sobue T. The standardized development method of the Japanese Guidelines for Cancer Screening. Japan J Clinical Oncol 2008;38:288-95.
4. ERSPC (European Randomized Study of Screening for Prostate Cancer). http://www.erspc.org/
5. PLCO?Prostate, Lung, Colorectal and Ovarian)Publications. http://prevention.cancer.gov/programs-resources/groups/ed/programs/plco
6. Harris R, Lohr KN. Screening for prostate cancer: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
7. Friedman GD, Hiatt RA, Quesenberry CP, Jr, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991;337:1526-9.
8. Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. Screening digital rectal examination and prostate cancer mortality: A case-control study. J Med Screen 1998;5:99-103.
9. Weinmann S, Richert-Boe K, Glass AG, Weiss NS. Prostate cancer screening and mortality: A case-control study (United States). Cancer Causes Control 2004;15:133-8.
10. Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, et al. Screening digital rectal examination and prostate cancer mortality: A population-based case-control study. Urology 1998;52:173-9.
11. Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 1994;3:105-11.
12. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Prac 2003;16:95-101.
13. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59:311-8.
14. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38: 83-91.
15. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomized controlled trial in Sweden. Eur Urol 2004;46:717-24.
16. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659-64.
17. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. A Cochrane database of systematic review. Cancer Causes Control 2007;18:279-85.
18. Ciatto S, Gervasi G, Gorini G, Lombardi C, Zappa M, Crocetti E. Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993. Eur J Cancer 2006;42:1858-62.
19. Nakagawa S, Nakamura A, Watanabe H. A case-control study on the interval of mass screening for prostate cancer. Japan J Urol 1998;89:894-8.
20. Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, et al. Screening with prostate specific antigen and metastatic prostate cancer risk: A population based case-control study. J Urol 2005;174:495-9.
21. Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, et al. The effectiveness of screening for prostate cancer: A nested case- control study. Arch Intern Med 2006;166:38-43.
22. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740.
23. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ 2002;166:586-91.
24. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: An analysis of mortality change by screening intensity. CMAJ 2003;168:31-5.
25. La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epidemiology of prostate cancer in the Umbria region of Italy: Evidence of opportunistic screening effects. Urology 2003;62:1040-4.
26. Threlfall TJ, English DR, Rouse IL. Prostate cancer in West Australia: trends in incidence and mortality from 1985 to 1996. Med J Aus 1998;169:21-4.
27. Skarsgard D, Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Cause Control 2000;11:79-88.
28. Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int 2000;85:1058-62.
29. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971-1995. Eur J Cancer 1998;34:705-9.
30. Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: Increased risk or increased detection? BJU Int 2000;85:463-73.
31. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted Country. Minn J Urol 1999;161:529-33.
32. Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004;160:1059-69.
33. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005;14:590-5.
34. Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: The decrease is continuing and spreading. Cancer Causes Control 2004;15:237-41.
35. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006;164:376-84.
36. Vutuc C, Schernhammer ES, Haidinger G, Waldhor T. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr 2005;117:457-61.
37. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-52.
38. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
39. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 1995;154:1085-9.
40. Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, et al. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996;156:2462-8.
41. Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000;56:278-82.
42. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: Follow up study with a bank of 21,000 sera in Finland. J Urol 2001;166:2189-92.
43. van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Rotterdam. J Natl Cancer Inst 2003;95:1462-6.
44. Auvinen A, Maattanen L, Finne P, Stenman UH, Aro J, Juusela H, et al. Test sensitivity of prostate-specific antigen in the Finnish randomized prostate cancer screening trial. Int J Cancer 2004;111:940-3.
45. McLernon DJ, Donnan PT, Gray M, Weller D, Sullivan F. Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen 2006;13:102-7.
46. Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH. Tumor features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006;50:70-5.
47. Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002;50:262-9.
48. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: Estimating the magnitude of overdetection. CMAJ 1998;159:1368-72.
49. Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000;85:1078-84.
50. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
51. Auvin A, Maattanen L, Stenman UH, Tammela T, Rannikko S, Aro J, et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002;13:279-85.
52. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
53. Törnblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108:122-9.
54. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: Evaluation of complication rates and risk factors within a population-based screening program. Urology 1997;49:875-80.
55. Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: A prospective, controlled study. Urology 2002;60:846-50.
56. Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, et al. Screening for prostate cancer: Updated experience from the Tyrol study. Can J Urol 2005;12(Suppl 1):7-13.
57. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8.
58. Cooner WH, Mosley BR, Rutherford CL, Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;167:966-75.
59. Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature. J Urol 1998;160:2115-20.
60. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J Urol 2001;166:856-60.
61. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002;60:826-30.
62. Crawford ED, Haynes AL, Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982;127:449-51.
63. ron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study. BJU Int 2000;85:682-5.
64. ggman M, Magnusson A. Determinants of complications after multiple transrectal core biopsies of the prostate. Eur Radiol 1996;6:457-61.
65. Kumagai A, Ogawa D, Koyama T, Takeuchi I, Ohama I. A case report of fournier's gangrene in a diabetic patient induced by transrectal prostate biopsy (TRPB). Jpn J Urol 2002;93:648-51.
66. Hasegawa T, Siomura T, Yamada H, Ito H, Katao N, Hasegawa M, et al. Fatal septic shock caused by transrectal needle biopsy of the prostate; a case report. Jn J Inf 2002;76:893-7.
67. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000;283:354-60.
68. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002;95:2397-407.
69. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993;269: 2633-6.
70. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
71. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-67.
72. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-92.
73. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619-28.
74. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 1998;16:275-83.
75. Arai Y, Egawa S, Tobisu K, Sagiyama K, Sumiyoshi Y, Hashine K, et al. Radical retropubic prostatectomy: Time trends, morbidity and mortality in Japan. BJU Int 2000;85:287-94.
76. Hisasue S, Takahashi A, Kato R, Shimizu T, Masumori N, Itoh N, et al. Early and late complications of radical retropubic prostatectomy: experience in a single institution. Jpn J Clin Oncol 2004;34:274-9.
77. Schröder FH, Habbema DF, Roobol MJ, Bangma CH. Prostate cancer in the Swedish section of ERSPC-evidence for less metastases at diagnosis but not for mortality reduction. Eur Urol. 2007;51:588-90.
78. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
79. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192-9.
80. Lim LS, Sherin K, the ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164.
81. Ministry of Labour and Health. Cancer Screening Committee. Report for implementations and fund for cancer screening programs in local municipalities; 2007 (in Japanese).
82. Mettlin C. Impact of screening on prostate cancer rates and trends. Microsc Res Tech 2000;51:415-8.
83. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998;9:519-27.
84. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001;23:181-6.
85. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-1997) in East Asia, Europe and USA, from cancer incidence in five continents. Jpn J Clin Oncol 2007;37:556-7.
86. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57:90-104.
87. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology 2000;14:267-86.
88. Ito K, Kakehi Y, Naito S, Okuyama A. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol 2008;15:763-8.
89. Heidenreich A, Aus G, Michel Bolla M, Joniau S, Matveev VB, Schmid HS, et al. EAU Guidelines on Prostate Cancer. Eur Urol 2008;53:68-80.
90. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localized prostate cancer. Health Technol Assess 1997;1:19-23.
91. NHS National Cancer Screening Programmes. Prostate Cancer Risk Management. http://www.cancerscreening.nhs.uk/prostate/index.html.
92. European Code Against Cancer third edition. http://www.cancercode.org/ add_items.htm
93. Schersten T, Baile A, Asua J, Jonsson E. Prostate Cancer Screening: Evidence Synthesis and Update Statements of Findings. INAHTA: International Network of Agencies for Health Technology Assessment. http://inahta.episerverhotell.net/Publications/Joint-Synthesis/2314/ 1999.